|
|
The effect of Spironolactone combined with Amlodipine Mesylate Tablets in the treatment of elderly hypertensive heart disease |
LU Li-hua LIAO Tong LI Huan-lun GU Zhen-tuo |
Dalang Hospital of Dongguan City,Guangdong Province,Dongguan 523770,China |
|
|
Abstract Objective To investigate the effect of Spironolactone combined with Amlodipine Mesylate Tablets in the treatment of elderly hypertensive heart disease.Methods A total of 148 elderly patients with hypertensive heart disease treated in our hospital from January 2014 to January 2017 were selected and they were divided into the control group(n=74)and the observation group (n=74)according to the random digital table method.The control group was treated with routine treatment and nursing,and the observation group was treated with Spironolactone and Amlodipine Mesylate Tablets on the basis of the control group.The blood pressure (SBP,DBP),curative effect and LVEDVI,LVESVI,LVEDD,IVST,LVPWT indicators,VE/VA,LVEF,Tei index and other indicators before and after treatment of patients in the two groups were statistically analyzed.Results Before treatment,there is no significant difference in blood pressure between the two groups(P>0.05).After treatment,the improvement of SBP and DBP level of the observation group is significantly higher than that in the control group (P<0.05).The total effective rate of the observation group is 86.49%,which was obviously higher than that of the control group (59.46%)(P<0.05).Before treatment,there are no significant differences in LVEDVI,LVESVI,LVEDD,IVST and VE/VA,LVEF,LVPWT index and Tei index(P>0.05),after treatment,all parameters in the observation group were significantly improved (P<0.05),only LVEDVI,LVESVI and LVEF index in the control group were improved significantly (P<0.05),the degree of improvement in the observation group was higher than that of the control group (P<0.05).Conclusion Spironolactone combined with Amlodipine Mesylate Tablets can effectively improve left ventricular hypertrophy and remodeling in hypertensive patients,is beneficial for relieving diastolic dysfunction,reduce blood pressure,and ensure the treatment effect of patients.
|
|
|
|
|
[1] |
孙宁玲,霍勇,王继光,等.难治性高血压诊断治疗中国专家共识[J].中国介入心脏病学杂志,2013,5(2):5-12.
|
[2] |
唐立健,乜金茹.农村地区50岁及以上高血压患者血压控制情况及其影响因素研究[J].东南大学学报(医学版),2016,35(4):595-598.
|
[3] |
胥智勇,敬莉蓉,杜华.缬沙坦治疗慢性肾小球肾炎合并高血压患者的临床效果分析[J].检验医学与临床,2017,14(A01):159-161.
|
[4] |
王飞,史长城,朱洁瑾,等.临床药师参与高血压管理对血压控制的 Meta 分析[J].中国现代应用药学,2016,33(11):1448-1452.
|
[5] |
孔琳姝,翟小洁,韩梅,等.高血压合并甲状腺功能亢进临床预后分析[J].临床军医杂志,2016,44(12):1282-1284.
|
[6] |
张澍,华伟.2012ESC急性和慢性心力衰竭诊断与治疗指南解读[J].中华心律失常学杂志,2012,16(5):379-381.
|
[7] |
于凤霞.奥美沙坦酯氢氯噻嗪治疗高血压的临床研究[J].现代药物与临床,2016,31(1):50-53.
|
[8] |
张亚西,王安伟,郑爱华.比索洛尔在高血压慢性心力衰竭患者左心室重构中的作用[J].中国医药导报,2014,11(7):65-68.
|
[9] |
周江花.24 h动态心电图监测对高血压性心脏病的诊断价值[J].检验医学与临床,2014,11(18):2591.
|
[10] |
李艳,周欣荣,孙惠萍,等.血栓前状态分子标志物的变化在不稳定型心绞痛合并高血压患者中的价值[J].血栓与止血学,2017,23(1):32-35.
|
[11] |
任志静,张晶,丛洪良.H型高血压与左心室重构的关系探讨[J].天津医药,2016,44(3):356-359.
|
[12] |
王磊,魏新伟,于芳.不同降压药物联合治疗对老年高血压患者血压变异性的影响[J].天津医药,2016,44(1):105-109.
|
[13] |
孟莉娟,邹译娴,欧阳征仁,等.斑点追踪成像技术对原发性高血压伴舒张性心力衰竭患者左心室整体收缩功能的临床评价[J].中南医学科学杂志,2016,44(5):519-522.
|
[14] |
高俊明,聂彦阁,郭利,等.复方丹参滴丸联合胸腺五肽治疗高血压心脏病的疗效与安全性研究[J].医学临床研究,2017,34(7):1411-1413.
|
[15] |
杜微微.急性冠状动脉综合征合并高血压患者PCI术后肾功能变化及影响因素分析[J].医学临床研究,2016,33(9):1849-1851.
|
[16] |
谢永进,盖鲁粤.血管紧张素Ⅱ致心肌纤维化及其信号转导机制研究进展[J].解放军医学院学报,2014,35(6):630-633.
|
[17] |
耿涛,戴士鹏,张建刚,等.螺内酯对收缩性心力衰竭伴轻度肾功能不全患者的有效性和安全性研究[J].河北医科大学学报,2016,37(1):13-17.
|
[18] |
戴士鹏,马增才,张建刚,等.螺内酯在75岁以上老年收缩性心力衰竭患者中应用的安全性研究[J].实用老年医学,2015,29(6):487-490.
|
|
|
|